Akari Therapeutics Plc 10-Q — AI Bull & Bear Analysis

The 10-Q filing reveals a company at a critical crossroads, balancing a promising scientific pivot against a looming liquidity crisis. On one hand, the transition to a lean, AKTX-101-focused model and the engagement of WuXi Biologics suggest a viable path toward clinical validation. On the other hand, the 'going concern' warning and the massive impairment of assets from the Peak Bio acquisition indicate that the market has already priced in a high probability of failure. The overall impact of the filing is a high-risk, high-reward scenario where the company's survival depends entirely on its ability to secure capital in the next 90 days. If Akari can leverage its ASCO 2026 data to secure a strategic partner or a fresh equity infusion, the platform's novel biology could offer a massive upside. However, the current financial trajectory suggests a narrow window of opportunity before the cash runway expires.